Published in Immunol Rev on April 01, 2001
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
The host genetic diversity in malaria infection. J Trop Med (2012) 1.08
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes. Blood (2011) 1.02
Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep (2013) 0.99
A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol (2005) 0.99
Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun (2010) 0.94
Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces. Protein Sci (2004) 0.92
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology (2003) 0.90
Mathematical framework for human SLE Nephritis: disease dynamics and urine biomarkers. Theor Biol Med Model (2010) 0.85
SIRPα/CD172a and FHOD1 are unique markers of littoral cells, a recently evolved major cell population of red pulp of human spleen. J Immunol (2012) 0.84
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol (2016) 0.83
Carbamylation of immunoglobulin abrogates activation of the classical complement pathway. Eur J Immunol (2014) 0.81
Frequencies of peripheral blood myeloid cells in healthy Kenyan children with alpha+ thalassemia and the sickle cell trait. Am J Trop Med Hyg (2006) 0.80
Protection of host cells by complement regulators. Immunol Rev (2016) 0.79
Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Mol Immunol (2011) 0.78
Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model. J Neuroimmunol (2009) 0.78
A polymorphism in the type one complement receptor (CR1) involves an additional cysteine within the C3b/C4b binding domain that inhibits ligand binding. Mol Immunol (2007) 0.78
Erythrocyte complement receptor 1 (CR1) expression level is not associated with polymorphisms in the promoter or 3' untranslated regions of the CR1 gene. Int J Immunogenet (2006) 0.77
The immune adherence receptor CR1-like existed on porcine erythrocytes membrane. Sci Rep (2015) 0.75
Red blood cell complement receptor one level varies with Knops blood group, α(+)thalassaemia and age among Kenyan children. Genes Immun (2016) 0.75
Genomic analysis reveals a duplication of eight rather than seven short consensus repeats in primate CR1 and CR1L: evidence for an additional set shared between CR1 and CR2. Immunogenetics (2004) 0.75
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker. Kidney Int (2007) 2.84
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82
Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest (1966) 1.81
The living donor in kidney transplantation. Ann Intern Med (1987) 1.81
Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA (1976) 1.77
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1991) 1.66
Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest (1984) 1.46
Renoprotective therapy: how good can it get? Kidney Int (2000) 1.39
Therapy of membranous nephropathy: what to do after the after (meta) analyses. J Am Soc Nephrol (1995) 1.39
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int (2007) 1.18
Renal artery dissection causing renal infarction in otherwise healthy men. Am J Kidney Dis (1997) 1.17
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol (2012) 1.10
The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int (1987) 1.07
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol (1987) 1.04
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis (1999) 1.02
Diagnostic significance of hypocomplementemia. Kidney Int (1991) 0.97
Interactions between precipitating and nonprecipitating antibodies in the formation of immune complexes. J Immunol (1987) 0.97
Measurement of the fractional uptake of macromolecules by the renal vascular bed compared to other vascular beds. J Lab Clin Med (1976) 0.97
Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol (1990) 0.95
Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol (1999) 0.93
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol (2006) 0.92
Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus (2011) 0.92
Subacute bacterial endocarditis masquerading as type III essential mixed cryoglobulinemia. J Am Soc Nephrol (1997) 0.91
Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int (1991) 0.90
Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor. Clin Immunol Immunopathol (1984) 0.90
Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus (2012) 0.85
Immune complexes bind preferentially to specific subpopulations of human erythrocytes. Clin Immunol Immunopathol (1990) 0.85
Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates. J Lab Clin Med (1990) 0.84
Of mice and men: the relevance of the mouse to the study of human SLE. Immunol Res (2001) 0.83
Reversal of chronic end-stage renal failure due to myeloma kidney. Ann Intern Med (1979) 0.83
Rapidly progressive glomerulonephritis superimposed on diabetic glomerulosclerosis. Recognition and treatment. JAMA (1982) 0.82
Renal subcapsular pressure--a new intrarenal pressure measurement. Am J Physiol (1971) 0.82
Effect of renal decapsulation on renal function. Am J Physiol (1975) 0.80
Renal artery pressure gradients in patients with angiographic evidence of atherosclerotic renal artery stenosis. Am J Kidney Dis (1994) 0.80
Stability of renal transplant function with alternate-day corticosteroid therapy. JAMA (1980) 0.79
Renal autotransplantation in the loin pain-hematuria syndrome: a cautionary note. Am J Kidney Dis (1992) 0.78
Simple method for monitoring 24-hour urinary urea nitrogen excretion. J Lab Clin Med (1986) 0.78
Adverse effect of exercise on immune complex-mediated glomerulonephritis. Nephron (1985) 0.78
A comparison of taste acuity for salt in renal patients vs. normal subjects. J Am Diet Assoc (1987) 0.78
Renal expansion in saline loading. Am J Physiol (1974) 0.78
Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplant Proc (1980) 0.77
Primary hypothyroidism in chronic renal failure. Clin Nephrol (1986) 0.77
Plasmapheresis in the treatment of renal allograft rejection. Proc Clin Dial Transplant Forum (1979) 0.76
Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int (1996) 0.76
Human erythrocytes inhibit complement-mediated solubilization of immune complexes. J Immunol (1989) 0.76
Whole kidney volume/pressure relationships. Kidney Int (1975) 0.76
Management of urinary tract infections. N Engl J Med (1994) 0.75
Renal volume-pressure and functional relationships in acute allograft rejection. Transplantation (1980) 0.75
[Complement in kidney diseases]. Rev Clin Esp (1996) 0.75
Body at work. Occup Health Saf (1992) 0.75
Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. Clin Pharm (1985) 0.75
Habitual excessive dietary salt intake and blood pressure levels in renal transplant recipients. Am J Med (1982) 0.75
Glomerular basement membrane splitting and microaneurysm formation associated with nitrosourea therapy. Am J Nephrol (1985) 0.75
Angiotensin as a possible intrarenal hormone in isolated dog kidneys. Circ Res (1973) 0.75
Apheresis is of value in SLE. Trans Am Soc Artif Intern Organs (1984) 0.75
Operative risks: the clinical evaluation and management of disorders of water and electrolyte balance. Clin Obstet Gynecol (1973) 0.75
Effect of moderate daily exercise on acute glomerulonephritis. Nephron (1981) 0.75
Platelet involvement in experimental immune complex-mediated glomerulonephritis in the nonhuman primate. Kidney Int (1993) 0.75
Method for detecting a progressive renal disorder superimposed on a preexisting progressive renal disorder. Am J Kidney Dis (1981) 0.75
Metacarpophalangeal joint replacement. Case report of 20-year follow-up. Phys Ther (1979) 0.75
Effects of immune complex formation and complement activation on circulating platelets in the primate. Clin Immunol (1999) 0.75
Effect of glucocorticoids on WBC counts in splenectomized renal transplant recipients. Arch Intern Med (1978) 0.75
On the natural tendency for renal disease to progress: can interventions slow this progression? Trans Assoc Life Insur Med Dir Am (1989) 0.75
Light-chain proteinuria: spurious false-negative reaction to sulfosalicylic acid. Ann Intern Med (1985) 0.75
Potassium depletion and hypercapnia. N Engl J Med (1969) 0.75
Infantile polycystic kidney disease in the adult. Arch Intern Med (1977) 0.75
Building peer contact within a group practice. Phys Ther (1979) 0.75
Skin depigmentation related to transdermal clonidine therapy. Arch Intern Med (1995) 0.75
Effect of expansion of renal parenchymal volume on renal function. Nephron (1978) 0.75
Analytical focus reduces anxiety over CTD claims. Occup Health Saf (1993) 0.75